Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022.
People with immunocompromising conditions (IC) are at increased risk of severe COVID-19 and death. These individuals show weaker immunogenicity following vaccination than individuals without IC, yet immunogenicity after SARS-CoV-2 infection is poorly understood. To address this gap, the presence of...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0313620 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533193560260608 |
|---|---|
| author | Anna Bratcher Jefferson M Jones William A Meyer Rehan Waheed Huda Yazgi Aaron Harris Adi V Gundlapalli Kristie E N Clarke |
| author_facet | Anna Bratcher Jefferson M Jones William A Meyer Rehan Waheed Huda Yazgi Aaron Harris Adi V Gundlapalli Kristie E N Clarke |
| author_sort | Anna Bratcher |
| collection | DOAJ |
| description | People with immunocompromising conditions (IC) are at increased risk of severe COVID-19 and death. These individuals show weaker immunogenicity following vaccination than individuals without IC, yet immunogenicity after SARS-CoV-2 infection is poorly understood. To address this gap, the presence of infection-induced antibodies in sera following a positive COVID-19 test result was compared between patients with and without IC. A commercial laboratory provided patient data gathered during July 2020-February 2022 on COVID-19 viral test results and antibody assay results, which included infection-induced (anti-N) antibody presence. Participants were categorized into having or not having IC based on if there was an indicative diagnostic code on their health record for a five-year period prior to the study period. Anti-N presence in sera from people with a positive COVID-19 test result was compared by IC status for four post-infection periods: 14-90, 91-180, 181-365, and 365+ days. A longitudinal, logistic regression produced adjusted odds ratios comparing anti-N prevalence among specimens with and without associated IC, adjusted for age, sex, residence in a metro area, and social vulnerability index (SVI) tertile. Data included 17,025 anti-N test results from 14,690 patients, 1,424 (9.7%) of which had at least one IC on record. In an adjusted comparison to patients without IC, patients with any IC were 0.61 times as likely to have infection-induced antibodies (99% CI: 0.40-0.93), during the 14-90 days following infection. Similar patterns were found when comparing people with two specific types of IC to people without any IC: (1) solid malignancies and (2) other intrinsic immune conditions. These findings stress the importance of prevention measures for people with IC, such as additional vaccination doses and consistent mask use before and after a documented infection. |
| format | Article |
| id | doaj-art-c3bce1f28f324214a6faa53a9d32db79 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-c3bce1f28f324214a6faa53a9d32db792025-01-17T05:31:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031362010.1371/journal.pone.0313620Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022.Anna BratcherJefferson M JonesWilliam A MeyerRehan WaheedHuda YazgiAaron HarrisAdi V GundlapalliKristie E N ClarkePeople with immunocompromising conditions (IC) are at increased risk of severe COVID-19 and death. These individuals show weaker immunogenicity following vaccination than individuals without IC, yet immunogenicity after SARS-CoV-2 infection is poorly understood. To address this gap, the presence of infection-induced antibodies in sera following a positive COVID-19 test result was compared between patients with and without IC. A commercial laboratory provided patient data gathered during July 2020-February 2022 on COVID-19 viral test results and antibody assay results, which included infection-induced (anti-N) antibody presence. Participants were categorized into having or not having IC based on if there was an indicative diagnostic code on their health record for a five-year period prior to the study period. Anti-N presence in sera from people with a positive COVID-19 test result was compared by IC status for four post-infection periods: 14-90, 91-180, 181-365, and 365+ days. A longitudinal, logistic regression produced adjusted odds ratios comparing anti-N prevalence among specimens with and without associated IC, adjusted for age, sex, residence in a metro area, and social vulnerability index (SVI) tertile. Data included 17,025 anti-N test results from 14,690 patients, 1,424 (9.7%) of which had at least one IC on record. In an adjusted comparison to patients without IC, patients with any IC were 0.61 times as likely to have infection-induced antibodies (99% CI: 0.40-0.93), during the 14-90 days following infection. Similar patterns were found when comparing people with two specific types of IC to people without any IC: (1) solid malignancies and (2) other intrinsic immune conditions. These findings stress the importance of prevention measures for people with IC, such as additional vaccination doses and consistent mask use before and after a documented infection.https://doi.org/10.1371/journal.pone.0313620 |
| spellingShingle | Anna Bratcher Jefferson M Jones William A Meyer Rehan Waheed Huda Yazgi Aaron Harris Adi V Gundlapalli Kristie E N Clarke Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022. PLoS ONE |
| title | Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022. |
| title_full | Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022. |
| title_fullStr | Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022. |
| title_full_unstemmed | Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022. |
| title_short | Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022. |
| title_sort | anti nucleocapsid sars cov 2 antibody seroprevalence in previously infected persons with immunocompromising conditions united states 2020 2022 |
| url | https://doi.org/10.1371/journal.pone.0313620 |
| work_keys_str_mv | AT annabratcher antinucleocapsidsarscov2antibodyseroprevalenceinpreviouslyinfectedpersonswithimmunocompromisingconditionsunitedstates20202022 AT jeffersonmjones antinucleocapsidsarscov2antibodyseroprevalenceinpreviouslyinfectedpersonswithimmunocompromisingconditionsunitedstates20202022 AT williamameyer antinucleocapsidsarscov2antibodyseroprevalenceinpreviouslyinfectedpersonswithimmunocompromisingconditionsunitedstates20202022 AT rehanwaheed antinucleocapsidsarscov2antibodyseroprevalenceinpreviouslyinfectedpersonswithimmunocompromisingconditionsunitedstates20202022 AT hudayazgi antinucleocapsidsarscov2antibodyseroprevalenceinpreviouslyinfectedpersonswithimmunocompromisingconditionsunitedstates20202022 AT aaronharris antinucleocapsidsarscov2antibodyseroprevalenceinpreviouslyinfectedpersonswithimmunocompromisingconditionsunitedstates20202022 AT adivgundlapalli antinucleocapsidsarscov2antibodyseroprevalenceinpreviouslyinfectedpersonswithimmunocompromisingconditionsunitedstates20202022 AT kristieenclarke antinucleocapsidsarscov2antibodyseroprevalenceinpreviouslyinfectedpersonswithimmunocompromisingconditionsunitedstates20202022 |